pre-IPO PHARMA

COMPANY OVERVIEW

VLP Therapeutics, LLC (VLP) was established in 2012 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology.


LOCATION

  • Gaithersburg, MD, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Neurological Disorders
  • Oncology

  • WEBSITE

    https://vlptherapeutics.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Dec 27, 2021

    VLP Therapeutics raises $21M Series A-1 for cancer treatment vaccine, infectious diseases vaccine RandD


    Mar 15, 2021

    VLP Therapeutics raises $16M Series A for cancer treatment vaccine RandD


    Mar 15, 2021

    VLP Therapeutics names seasoned biotech venture capitalist Miwa Toyoda as CBO


    Feb 4, 2019

    VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine


    Dec 12, 2018

    VLP Therapeutics Awarded $3.9 million Grant by Global Health Innovative Technology Fund for Further Development of Dengue Vaccine


    For More Press Releases


    Google Analytics Alternative